华纳药厂公告称，其全资子公司手性药物公司收到巴西国家卫生监督局签发的药品生产质量管理规范 （GMP）认证证书，认证范围为化学原料药磷霉素氨丁三醇，有效期至2028年1月19日。磷霉素氨丁三 醇是治疗尿路感染等制剂产品的原料药。此次认证为产品进入巴西市场创造条件，利于拓展国际市场、 提升国际竞争力，但国际原料药业务受政策和市场环境影响，有不确定性。 ...

证书编号：No. CEP 2024-020 - Rev 00 生产地址：浙江省台州市椒江区外沙路46号 证券代码：600267 证券简称：海正药业 公告编号：临2026-15号 浙江海正药业股份有限公司 关于替格瑞洛原料药获得CEP证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 近日，浙江海正药业股份有限公司（以下简称"公司"）收到欧洲药品质量管理局（European Directorate for the Quality of Medicines & HealthCare，以下简称"EDQM"）签发的替格瑞洛原料药欧洲药典适用性 认证证书（Certificate of Suitability to Monograph of European Pharmacopoeia，以下简称"CEP证书"），现 就相关情况公告如下： 一、CEP证书相关信息 药品名称：TICAGRELOR/替格瑞洛 产品剂型：原料药 发证机构：欧洲药品质量管理局（EDQM） 二、药品的其他相关情况 替格瑞洛适用于急性冠状动脉综合征（ACS）的治 ...

Financial Performance - The company provided revenue guidance for Q2 of FY2026, estimating between 150 million to 160 million yuan, representing a quarter-over-quarter growth of 18% to 25.9% [2] Business Expansion - The company plans to continue expanding its direct retail stores in top-tier shopping districts in major cities such as Beijing, Shanghai, Guangzhou, and Shenzhen, with four brand stores set to open in Beijing and Chongqing from late December 2025 to early January 2026 [3] - The company is also making strides in international market expansion, with products entering nearly 20 countries through a distribution network, including North America, Europe, Southeast Asia, and the Middle East [5] Industry Resource Advantages - The company possesses 11 proprietary IPs and 6 licensed IPs, with the star IP WAKUKU generating 89.73 million yuan in revenue during Q1 of FY2026. The monthly production of plush blind boxes has significantly increased, reaching 35 times the output of January 2025 by October 2025, which may impact future business growth [4]

Company Developments - RLX Technology has completed the sample preparation for its self-developed oral nicotine product in 2024, with plans to launch it in the European and American markets by 2026, aiming to expand the smokeless tobacco product market through more convenient usage [2] - The company has initiated the "Seeing Love: Guide Dog Partner Program," which will run from 2025 to 2026, planning to donate 4 million yuan for the training, medical care, and education of 20 guide dogs, with the first batch of 10 guide dogs delivered in 2025 [3] Business Progress - According to the Q3 2025 financial report, RLX Technology's international business revenue has reached 72%, with ongoing expansion in the Asia-Pacific and European markets through mergers and acquisitions, such as the completion of a European acquisition in May 2025, indicating a potential for further localization efforts [4] Product Development - In addition to the oral nicotine product, the company has launched nicotine oral films in the U.S. market and continues to develop heat-not-burn (HNB) and other new tobacco products to expand its global product matrix [5]

经济观察网2026年2月11日，美国财政部宣布允许美国公司向委内瑞拉提供提升石油产量所需的设备和 技术，哈里伯顿被明确列为可开展相关业务的企业之一。这一政策调整可能为哈里伯顿的国际市场拓展 提供新机遇，但需关注地缘政治风险。 股票近期走势 近7天(2026年2月5日至11日)，哈里伯顿(HAL.N)股价区间累计上涨2.01%，振幅达6.79%。2月11日单日 涨幅为2.97%，收盘报35.03美元，成交额约4.80亿美元；2月6日因市场情绪推动单日上涨3.37%。区间 最高价为35.29美元(2月11日)，最低价为32.96美元(2月5日)，总成交额约20.01亿美元。同期，油气设备 与服务板块上涨4.58%，美股大盘道指微跌0.13%。 财报分析 哈里伯顿2025年第四季度营收56.57亿美元，调整后每股收益0.69美元，均超出市场预期。国际业务收入 同比增长2.9%至35亿美元，主要受益于拉丁美洲、北海等地区需求增长。尽管财报于1月21日披露，但 其超预期表现近期仍被市场关注，支撑股价韧性。 以上内容基于公开资料整理，不构成投资建议。 ...

Group 1 - The U.S. Treasury Department has announced a policy allowing American companies to provide equipment and technology necessary for increasing oil production in Venezuela, with Halliburton explicitly listed as one of the companies eligible to conduct related business. This policy shift may present new opportunities for Halliburton's international market expansion, although geopolitical risks should be monitored [1] Group 2 - Over the past week, Halliburton's stock price has increased by 2.01%, with a volatility of 6.79%. On February 11, the stock rose by 2.97%, closing at $35.03 with a trading volume of approximately $480 million. On February 6, market sentiment drove a single-day increase of 3.37%. The stock reached a high of $35.29 and a low of $32.96 during this period, with a total trading volume of about $2 billion. In comparison, the oil and gas equipment and services sector rose by 4.58%, while the broader U.S. market, represented by the Dow Jones, saw a slight decline of 0.13% [2] Group 3 - Halliburton reported revenue of $5.657 billion for the fourth quarter of 2025, with adjusted earnings per share of $0.69, both exceeding market expectations. International business revenue grew by 2.9% year-over-year to $3.5 billion, primarily driven by increased demand in Latin America and the North Sea. Although the earnings report was disclosed on January 21, its better-than-expected performance has continued to attract market attention, supporting the resilience of the stock price [3]

Core Viewpoint - The company has received a drug registration certificate for Tadalafil 20mg tablets from the Ghana Food and Drug Administration, marking a significant step in its international market expansion [1][3]. Group 1: Drug Registration Details - Drug Name: TADALAFIL 20mg TABLETS - Dosage Form: Tablet - Specification: 20mg - Registration Number: FDA/GD.255-120251 - Certificate Number: FDA-GH-77157971 - Manufacturer: Jiangsu Lianhuan Pharmaceutical Co., Ltd. - Address: No. 9, Health Road, Yangzhou Biohealth Industry Park, Yangzhou, Jiangsu Province - Validity Period: Until December 31, 2030 [1]. Group 2: Market Position and Financial Impact - The company is the only Chinese enterprise holding the Tadalafil 20mg drug registration certificate in Ghana [2]. - The sales revenue for Tadalafil tablets in 2024 is projected to be 23.0793 million RMB [1]. - The registration allows for legal sales in Ghana, but the expected revenue impact on the company's overall performance is minimal due to the current lack of sales in the region [3].

Core Viewpoint - The company, Anhui Shanhe Pharmaceutical Excipients Co., Ltd., successfully passed its first on-site inspection by the U.S. FDA, indicating that its quality management system meets international standards, which is expected to facilitate the expansion into U.S. and other international markets [1]. Group 1: Stock Performance - As of February 4, 2026, the stock price of Shanhe Pharmaceutical Excipients closed at 15.77 yuan, reflecting a 2.8% increase from the previous trading day [1]. - The stock opened at 15.35 yuan, reached a high of 16.01 yuan, and a low of 15.28 yuan, with a trading volume of 2.75 billion yuan and a turnover rate of 8.84% [1]. Group 2: FDA Inspection - The company underwent an on-site inspection by the U.S. FDA from December 4 to December 5, 2025, covering six major systems: quality management, production management, facility and equipment management, laboratory quality control, material and packaging label management [1]. - The company received the FDA's Establishment Inspection Report (EIR), confirming that the inspection was completed successfully [1]. Group 3: Market Implications - The successful FDA inspection is expected to positively impact the company's domestic pharmaceutical excipients business by reducing reliance on imports [1]. - The company cautions investors about potential risks to overseas business due to market conditions, tariffs, and exchange rates [1].

Core Viewpoint - The company, Andavil (300719.SZ), has received acceptance of its ETSOA certification application from EASA, which will initiate the supplier development work for Airbus and open up international market opportunities [1] Group 1 - The company is planning to support related export products in the defense trade sector [1]

Core Viewpoint - The company believes that the Russian full-steel giant tire market is not a "vacuum" left by the exit of international brands like Michelin and Bridgestone, as competition continues to exist [1] Group 1: Market Potential - The company is experiencing continuous growth in the number of Russian customers as it further explores the Russian market, indicating significant market potential [1] - The establishment of a factory in Russia is expected to consolidate and expand the company's market share in Russia and radiate to the Central Asian region [1] Group 2: Competitive Advantage - The company aims to maintain its competitiveness in the Russian market by leveraging the trust established through deep cooperation with core customers, as well as the recognition of its product quality and specialized services [1]